IP Library Granted Patent US 7,329,500
Granted Patent B2
US 7,329,500 · App. 10/487,783 · Granted Feb 12, 2008

Patent

Assignee: ID Biomedical Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,329,500
App. No.
10/487,783
Granted
Feb 12, 2008
Kind
B2
Abstract

The present invention relates to polypeptides of Moraxella ( Branhamela ) catarrhalis which may be used for prophy-laxis, diagnostic and/or therapy purposes.

Claims (22)

1. An isolated polypeptide comprising

(a) an amino acid sequence at least 90% identical to the amino acid sequence set forth in SEQ ID NO:2; or

(b) an amino acid sequence at least 95% identical to the amino acid sequence set forth in SEQ ID NO:2,

wherein the polypeptide is capable of raising antibodies that specifically bind to the polypeptide comprising the amino acid sequence set forth in SEQ ID NO:2.

2. An isolated polypeptide comprising:

(a) the amino acid sequence set forth in SEQ ID NO:2;

(b) the polypeptide of (a), wherein the N-terminal methionine residue is deleted; or

(c) the polypeptide of (a), wherein the signal peptide amino acid sequence is deleted.

3. A pharmaceutical composition comprising a polypeptide according to either claim 1 or claim 2 and a pharmaceutically acceptable carrier, diluent or adjuvant.

4. A method for inducing an immune response against Moraxella catarrhalis in a host comprising administering to said host the composition according to claim 3 .

5. A method according to claim 4 wherein the host is a neonate, an infant or a child.

6. A method according to claim 4 wherein the host is an immunocompromised host.

7. A method according to claim 4 wherein the host is an adult.

8. A method of diagnosing Moraxella catarrhalis infection in a host susceptible to Moraxella catarrhalis infection comprising:

(a) obtaining a biological sample from a host;

(b) incubating one or more polypeptides according to either claim 1 or claim 2 with the biological sample to form a mixture; and

(c) detecting specifically bound polypeptide in the mixture which indicates the presence of an antibody that specifically binds to the Moraxella catarrhalis antigen thereby detecting Moraxella catarrhalis infection.

9. A method for the detection of an antibody that specifically binds to a Moraxella catarrhalis antigen in a biological sample containing or suspected of containing said antibody comprising:

(a) obtaining a biological sample from a host;

(b) incubating one or more polypeptides according to either claim 1 or claim 2 with the biological sample to form a mixture, and

(c) detecting specifically bound polypeptide in the mixture which indicates the presence of an antibody that specifically binds to the Moraxella catarrhalis antigen.

10. A kit comprising the polypeptide according to either claim 1 or claim 2 for detection or dialgnosis of Moraxella catarrhalis infection.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2006
From: SHIRE BIOCHEM INC.
To: ID BIOMEDICAL CORPORATION
Reel/Frame 018131/0564 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 26, 2004
From: MARTIN, DENIS; HAMEL, JOSEE; BRODEUR, BERNARD R.; RIOUX, STEPHANE; COUTURE, JULIE
To: SHIRE BIOCHEM INC.
Reel/Frame 015606/0959 →
Continuity (1)
Related Publication 20040242859A1 · Dec 2, 2004